Abstract
Conclusions
Generally speaking, our experience with these drugs in staphylococcic infections is in marked contrast to the decisively favorable results of sulfanilamide in hemolytic streptococcal infections. Disulfanilamide, by virtue of its apparent therapeutic effect over a limited time period has a certain promise, which, however, failed of clinical confirmation in the small number of cases observed. A more diversified experimental trial is merited. Both experimentally and clinically the results with “Di-Septal” in this preliminary study were essentially negative.
Get full access to this article
View all access options for this article.